Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis
Diseases of the Musculoskeletal System
What is the purpose of this trial?
To evaluate the efficacy of MT-7117 treatment in subjects with diffuse cutaneous systemic sclerosis (dcSSc) using the American College of Rheumatology Composite Response Index in Diffuse Systemic Sclerosis (ACR CRISS) at Week 52.
- Ages18 years - 75 years
- Trial withMitsubishi Tanabe Pharma Development America, Inc.
- Start Date12/15/2021
- End Date01/31/2023
- Last Updated11/11/2022
- Study HIC#2000028282